{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T06:59:18Z","timestamp":1779173958056,"version":"3.51.4"},"reference-count":19,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,5,7]],"date-time":"2025-05-07T00:00:00Z","timestamp":1746576000000},"content-version":"vor","delay-in-days":6,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100019573","name":"Amsterdam University Medical Centers","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100019573","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100016405","name":"European Atherosclerosis Society","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016405","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","lipidjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Clinical Lipidology"],"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1016\/j.jacl.2025.05.003","type":"journal-article","created":{"date-parts":[[2025,5,9]],"date-time":"2025-05-09T06:36:25Z","timestamp":1746772585000},"update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Global disparities in access to lipid-lowering therapies for patients with homozygous familial hypercholesterolemia \u2013 A physician survey"],"prefix":"10.1016","author":[{"given":"Willemijn A.M.","family":"Schonck","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Janneke W.C.M.","family":"Mulder","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8107-827X","authenticated-orcid":false,"given":"Tycho R.","family":"Tromp","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laurens F.","family":"Reeskamp","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G. Kees","family":"Hovingh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6870-9962","authenticated-orcid":false,"given":"Jeanine E. Roeters","family":"van Lennep","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3965-5912","authenticated-orcid":false,"given":"Dirk J.","family":"Blom","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"25","key":"10.1016\/j.jacl.2025.05.003_bib0001","doi-asserted-by":"crossref","first-page":"2277","DOI":"10.1093\/eurheartj\/ehad197","article-title":"2023 Update on European Atherosclerosis Society Consensus Statement on Homozygous Familial Hypercholesterolaemia: new treatments and clinical guidance","volume":"44","author":"Cuchel","year":"2023","journal-title":"Eur Heart J"},{"issue":"4","key":"10.1016\/j.jacl.2025.05.003_bib0002","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1097\/MOL.0000000000000686","article-title":"Evidence for improved survival with treatment of homozygous familial hypercholesterolemia","volume":"31","author":"Belanger","year":"2020","journal-title":"Curr Opin Lipidol"},{"key":"10.1016\/j.jacl.2025.05.003_bib0003","first-page":"111","author":"Mach","year":"2019","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacl.2025.05.003_bib0004","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1016\/j.atherosclerosis.2018.06.859","article-title":"Familial hypercholesterolemia treatments: guidelines and new therapies","volume":"277","author":"Raal","year":"2018","journal-title":"Atherosclerosis"},{"issue":"10326","key":"10.1016\/j.jacl.2025.05.003_bib0005","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1016\/S0140-6736(21)02001-8","article-title":"Worldwide experience of homozygous familial hypercholesterolaemia: retrospective cohort study","volume":"399","author":"Tromp","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.jacl.2025.05.003_bib0006","unstructured":"Bank TW. Data World Bank national accounts. GNI per capita, Atlas method (current US$) - high income, middle income, low income. 2024. https:\/\/datahelpdesk.worldbank.org\/knowledgebase\/articles\/906519-world-bank-country-and-lending-groups. Accessed February 15, 2025."},{"key":"10.1016\/j.jacl.2025.05.003_bib0007","unstructured":"Geoscheme UN. United Nations publication \"Standard Country or Area Codes for Statistical Use\" https:\/\/unstats.un.org\/unsd\/methodology\/m49\/. Accessed February 15, 2025."},{"issue":"1","key":"10.1016\/j.jacl.2025.05.003_bib0008","doi-asserted-by":"crossref","first-page":"75","DOI":"10.5334\/gh.1154","article-title":"World Heart Federation cholesterol Roadmap 2022","volume":"17","author":"Ray","year":"2022","journal-title":"Glob Heart"},{"issue":"9798","key":"10.1016\/j.jacl.2025.05.003_bib0009","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1016\/S0140-6736(11)61215-4","article-title":"Use of secondary prevention drugs for cardiovascular disease in the community in high-income, middle-income, and low-income countries (the PURE Study): a prospective epidemiological survey","volume":"378","author":"Yusuf","year":"2011","journal-title":"Lancet"},{"issue":"10","key":"10.1016\/j.jacl.2025.05.003_bib0010","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1016\/S2213-8587(18)30233-X","article-title":"Availability and affordability of essential medicines for diabetes across high-income, middle-income, and low-income countries: a prospective epidemiological study","volume":"6","author":"Chow","year":"2018","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"6","key":"10.1016\/j.jacl.2025.05.003_bib0011","doi-asserted-by":"crossref","first-page":"e340","DOI":"10.1016\/S2666-7568(21)00089-1","article-title":"The state of diabetes treatment coverage in 55 low-income and middle-income countries: a cross-sectional study of nationally representative, individual-level data in 680 102 adults","volume":"2","author":"Flood","year":"2021","journal-title":"Lancet Healthy Longev"},{"issue":"14","key":"10.1016\/j.jacl.2025.05.003_bib0012","doi-asserted-by":"crossref","DOI":"10.3390\/jcm13144160","article-title":"The hurdle of access to emerging therapies and potential solutions in the management of dyslipidemias","volume":"13","author":"Mansfield","year":"2024","journal-title":"J Clin Med"},{"issue":"10090","key":"10.1016\/j.jacl.2025.05.003_bib0013","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/S0140-6736(16)30947-3","article-title":"Drivers of poor medical care","volume":"390","author":"Saini","year":"2017","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.jacl.2025.05.003_bib0014","doi-asserted-by":"crossref","first-page":"e145","DOI":"10.1016\/S2214-109X(23)00488-6","article-title":"Inequalities in health system coverage and quality: a cross-sectional survey of four Latin American countries","volume":"12","author":"Roberti","year":"2024","journal-title":"Lancet Glob Health"},{"issue":"2","key":"10.1016\/j.jacl.2025.05.003_bib0015","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.atherosclerosissup.2014.07.006","article-title":"Coudray-Omnes C. Daily life, experience and needs of persons suffering from homozygous familial hypercholesterolaemia: insights from a patient survey","volume":"15","author":"Bruckert","year":"2014","journal-title":"Atheroscler Suppl"},{"issue":"3","key":"10.1016\/j.jacl.2025.05.003_bib0016","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/j.jacl.2019.02.001","article-title":"Clinical management, psychosocial characteristics, and quality of life in patients with homozygous familial hypercholesterolemia undergoing LDL-apheresis in Turkey: results of a nationwide survey (A-HIT1 registry)","volume":"13","author":"Kayikcioglu","year":"2019","journal-title":"J Clin Lipidol"},{"issue":"1","key":"10.1016\/j.jacl.2025.05.003_bib0017","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.atherosclerosis.2015.09.021","article-title":"Familial hypercholesterolaemia: a global call to arms","volume":"243","author":"Vallejo-Vaz","year":"2015","journal-title":"Atherosclerosis"},{"issue":"17","key":"10.1016\/j.jacl.2025.05.003_bib0018","doi-asserted-by":"crossref","first-page":"1874","DOI":"10.1093\/eurjpc\/zwad203","article-title":"Modelling the potential long-term survival benefit of evinacumab treatment versus. standard of care in patients with homozygous familial hypercholesterolaemia","volume":"30","author":"Gu","year":"2023","journal-title":"Eur J Prev Cardiol"},{"issue":"10466","key":"10.1016\/j.jacl.2025.05.003_bib0019","doi-asserted-by":"crossref","first-page":"1908","DOI":"10.1016\/S0140-6736(24)01309-6","article-title":"Non-communicable diseases: can implementation research change the game for policy and practice?","volume":"404","author":"Rasanathan","year":"2024","journal-title":"Lancet"}],"container-title":["Journal of Clinical Lipidology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1933287425002843?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1933287425002843?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,6,12]],"date-time":"2025-06-12T02:21:40Z","timestamp":1749694900000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1933287425002843"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5]]},"references-count":19,"alternative-id":["S1933287425002843"],"URL":"https:\/\/doi.org\/10.1016\/j.jacl.2025.05.003","relation":{},"ISSN":["1933-2874"],"issn-type":[{"value":"1933-2874","type":"print"}],"subject":[],"published":{"date-parts":[[2025,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Global disparities in access to lipid-lowering therapies for patients with homozygous familial hypercholesterolemia \u2013 A physician survey","name":"articletitle","label":"Article Title"},{"value":"Journal of Clinical Lipidology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jacl.2025.05.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Inc. on behalf of National Lipid Association.","name":"copyright","label":"Copyright"}]}}